Global Deals Network

In Detail:

Santaris and Enzon To Develop RNA Antagonists

Enzon Pharmaceuticals Inc.and Santaris Pharma A/S have agreed to co-develop and market a series of RNA antagonists based on Santaris's locked nucleic acid technology. Enzon will license two of Santaris's compounds and six other proprietary RNA antagonist candidates to combat oncology targets selected by Enzon. Santaris will have commercialization rights in Europe. Enzon will retain development and commercial rights in the US and other nonEuropean territories.

Nostrum Licenses Protein from Indian Research Institute

Nostrum Pharmaceuticals Inc. has acquired a worldwide license agreement from the Institute …